MS Society of Canada earmarks $1 million for CCSVI clinical trials

The Multiple Sclerosis Society of Canada will commit $1 million for a chronic cerebrospinal venous insufficiency (CCSVI) and MS pan-Canadian therapeutic clinical trial—if research projects into CCSVI funded by the society currently underway indicate such trials are warranted, Yves Savoie, the charity’s president and CEO announced today. “We want to hit the ground running when a therapeutic trial is warranted and approved,” Savoie said in a press release. “Ensuring funds are available to support a Canadian trial will accelerate our ability to get definitive answers to the questions people touched by MS urgently seek.” The charity, which hopes to secure additional funding from the federal and provincial governments, has been under attack by MS patients who must travel to offshore clinics to receive the procedure pioneered by Italian doctor Paolo Zamboni because it is not currently available in Canada.

Globe and Mail

MS Society